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1Motivation for pathway analyses
• How do the changes in omics data relate to known cellular 
functions?
• Are there specific cellular pathways / molecular networks which 
display an over-representation of changes in my data?
2Motivation (2): Complex diseases as pathway perturbations
Alterations in different biomolecules of a cellular pathway or
network can cause similar disruptions downstream
Example: Colorectal carcinoma
• Mutation deactivating APC has the same 
overall effect as mutations preventing degra-
dation of β-catenin (Segditsas et al., 2006)
 Strategy: Analyze alterations at the
level of molecular networks and
pathways to complement single
gene/protein level analyses Wnt/β-catenin signaling pathway(         = affected by disease-related
mutations)
3Motivation (3): The “curse of dimensionality“
When analyzing increasing
numbers of genes (features):
• the space spanned by these
features grows exponentially
(no. of features = no. of dimensions)
 the available data tends to
become sparse
 discrimination between
different sample groups
(e.g. patients vs. controls)
becomes more difficult
 Strategy: Use pathway activity
representations of the data
to reduce the number of
dimensions
4Pathway / gene set resources
• Many public databases on functional gene sets and pathways available
• Both generic, multi-organism pathway collections and specialized 
collections (e.g. disease pathways such as the PD map)
• Format standardization efforts underway (BioPax, SBGN/SBML)
5Representations of pathways / functional gene groups
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 Find gene sets whose 
members are enriched    
among the differentially 
expressed genes
 pure statistical scoring
GENE SETS NETWORKS
 Identify network regions
enriched in expression
alterations
 scoring topological +
expression criteria
 Score pathways with 
regulatory consistent 
expression alterations
 scoring topology + 
expression changes + 
consistency criteria
DIAGRAMS
6Inconsistencies between pathway definitions
• Pathways are usually manually curated
 subjective decisions on members & 
boundaries
• A pathway defined for the same cellular 
process may look entirely different in two 
separate databases, e.g. “p53 signaling“:
BioCarta (p53 signaling) KEGG (p53 signaling)
Invitrogen iPath (p53 signaling)
7Improving pathway definitions using networks
• Questions: Can we make pathway definitions more objective? Can we 
improve existing pathways according to quantitative criteria (compactness, 
connectivity, density)? 
• Strategy: Use genome-scale networks to redefine pathways:
- protein-protein interactions
- genetic interactions
- gene co-expression relations
 large-scale, higher coverage, less biased
 can also reveal communication between
pathways (“cross-talk“)
8PathExpand: Network-based pathway extension
• Idea: Extend pathways by adding genes that are ”strongly connected“ to the 
pathway-nodes and increase the pathway-“compactness“ in a network.
Pathway extension criteria: Add a node v to set P if:
• v has a pathway-neighbour and degree(v) > 1; and
• #pathway-links(v,p) / #outside-links(v,p) > T1; or
• #triangle-links(v,p) / #possible_triangles(v,p) > T2; or
• #pathway-links(v,p) / #pathway-nodes(p) > T3; and
• avg. shortest path distance in {P,v} smaller than in P
black = pathway-nodes
red blue green = nodes added based on different criteria
...
...
...
9PathExpand: Example
Known cancer pathway: “BTG family proteins
and cell cycle regulation“ (BioCarta)
original pathway
added nodes
 Disconnected nodes  
become connected
 increased pathway-
compactness
Added known 
cancer gene
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PathExpand: Cross-validation
Question: Can randomly deleted genes in the original pathways be 
recovered by the expansion?
 3-step cross-validation procedure:
1. Randomly remove 10% of the pathway members (among
proteins with at least one partner in the pathway)
2. Apply the proposed extension procedure as well as 100
random extensions (random sampling among candidates)
3. Estimate p-value-like significance scores:
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PathExpand: Semantic similarity analysis
• Goal: Quantify pairwise 
similarities between 
protein annotations
Method: Jiang & 
Conrath‘s semantic GO 
term similarity measure
• Compute avg. GO-term 
similarity between 
pathway-proteins and 
added proteins
 compare to random  
extension model
12
Biological applications (1): Alzheimer‘s disease
• More than 20 proteins
annotated in our
PPI network
• 5 proteins added by the 
extension process (circled)
• 3 known to be associated
with the disease
• 2 novel candidates:
METTL2B, TMED10*
(*putative early-onset AD mutations reported)
KEGG Alzheimer disease pathway mapped 
on human PPI-network
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Biological applications (2): Interleukin signaling
• Complex system of
intracellular signaling 
cascades
• New putative pathway 
regulators identified 
• New “cross-talk proteins”
identified (associated
with multiple pathways) Two functions: pathway-regulation & pathway-
communication?
14
Biological applications (3): Enrichment analysis
Classical approach: Test enrichment of experimentally derived gene 
sets in cellular pathway members (one-sided Fisher exact test)
 Idea: replace original pathways by extended versions
Example: Enrichment analysis for pancreatic cancer mutated genes:
15
Biological applications (4): Pancreatic cancer
• “Cell cycle G1/S check 
point process” - extension 
procedure adds 7 proteins
• 6 of the added proteins are 
involved in cell cycle regulation
• the 7th (TGIF2) is known to be
mutated in pancreatic cancer
• points to functional role
of added proteins
16
PathExpand: Conclusion & Summary
• The method integrates two sources of information, extending 
canonical pathways using large-scale protein interaction data
• Three evaluated methods: cross-validation, GO-term semantic 
similarity and enrichment analysis
• Extended pathways are more compact and provide insights on 
on pathway regulators, the cross-talk between pathways and gene 
set functional enrichment
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